<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clonal hematopoiesis of indeterminate potential (CHIP) and related disorders of clonal hematopoiesis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clonal hematopoiesis of indeterminate potential (CHIP) and related disorders of clonal hematopoiesis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clonal hematopoiesis of indeterminate potential (CHIP) and related disorders of clonal hematopoiesis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mikkael A Sekeres, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">R Coleman Lindsley, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2059283798"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Clonal hematopoiesis (CH) refers to a genetically distinct subpopulation of myeloid cells, which share an acquired (ie, not inherited) mutation that distinguishes them from other tissues and unaffected hematopoietic cells. CH may be detected in healthy individuals with few or no hematologic manifestations; although clonality is also a feature of myelodysplastic syndromes, acute leukemias, and myeloproliferative neoplasms, these malignancies are generally associated with substantial hematologic findings.</p><p>Categories of CH include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clonal hematopoiesis of indeterminate potential (CHIP)</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clonal cytopenia of undetermined significance (CCUS)</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aging-related clonal hematopoiesis (ARCH)</strong></p><p></p><p>CHIP, CCUS, and ARCH are provisionally categorized according to the size of the clonal population and the presence of dysplasia and/or cytopenias  (<a class="graphic graphic_table graphicRef122233" href="/d/graphic/122233.html" rel="external">table 1</a>). It is important to recognize these conditions because some are associated with an increased risk for a hematologic malignancy, cardiovascular events, or other conditions.</p><p>This topic discusses the pathogenesis, epidemiology, evaluation, diagnosis, and management of CHIP, CCUS, and ARCH.</p><p>CCUS, ICUS, and myelodysplastic syndromes/neoplasms are discussed separately. (See  <a class="medical medical_review" href="/d/html/121985.html" rel="external">"Idiopathic and clonal cytopenias of uncertain significance (ICUS and CCUS)"</a> and  <a class="medical medical_review" href="/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"</a>.)</p><p>Clonality in lymphoid lineages, including monoclonal B cell lymphocytosis, monoclonal gammopathy of undetermined significance (MGUS), and lymphoproliferative disorders are described separately. (See  <a class="medical medical_review" href="/d/html/118011.html" rel="external">"Monoclonal B cell lymphocytosis"</a> and  <a class="medical medical_review" href="/d/html/6652.html" rel="external">"Diagnosis of monoclonal gammopathy of undetermined significance"</a>.)</p><p class="headingAnchor" id="H2341190949"><span class="h1">CLONALITY</span></p><p class="headingAnchor" id="H116184026"><span class="h2">Description and detection</span><span class="headingEndMark"> — </span>CH refers to a population of blood and/or bone marrow cells that share an acquired mutation. The presence of the mutation distinguishes the hematopoietic clone from unaffected blood cells and non-hematopoietic cells, which instead carry the corresponding unmutated ("wild-type") germline allele.</p><p>CH is often detected when next-generation sequencing (NGS) of DNA identifies a shared, acquired mutation in blood or marrow cells. Less commonly, CH is detected by chromosomal analysis (ie, karyotype), fluorescence in situ hybridization (FISH), single-gene polymerase chain reaction (PCR), or other techniques. Sensitivity to detection of CH varies with the detection method, but NGS is generally the most sensitive technique. (See  <a class="medical medical_review" href="/d/html/17039.html" rel="external">"Next-generation DNA sequencing (NGS): Principles and clinical applications"</a> and  <a class="medical medical_review" href="/d/html/2893.html" rel="external">"Tools for genetics and genomics: Cytogenetics and molecular genetics"</a>.)</p><p class="headingAnchor" id="H808748070"><span class="h2">Variant allele fraction (VAF)</span><span class="headingEndMark"> — </span>VAF refers to the percentage of mutated DNA sequencing reads at a given genetic locus. The threshold for VAF is often set at 1, 2, or 5 percent, depending on the testing facility, but the clinical significance of these proportions depends on test characteristics and disease context [<a href="#rid1">1</a>].</p><p>The ability to detect a clonal population of cells is a composite of the depth of sequencing (ie, the average number of times a given nucleotide position is sequenced) and the breadth/content of the platform. A common clinical application of NGS in this setting is using a "myeloid gene panel," which includes genes that are frequently mutated in myeloid malignancies. NGS can also be applied on the whole exome (ie, coding sequences of genes) or the whole genome. Detection of somatic mutations and measurement of VAF appear to be similar in paired bone marrow and peripheral blood specimens [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H710379955"><span class="h2">Relation of VAF to clone size</span><span class="headingEndMark"> — </span>VAF roughly parallels the size of the clone (ie, the percentage of blood/marrow cells that bear the mutation).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ratio of VAF:clone size</strong> – Most autosomal genes are present as two alleles, with one copy on each chromosome of an autosomal pair. In a clone of cells that have one mutated allele and one wild-type allele, the ratio of VAF:clone size would be 1:2. As an example, 10 percent VAF would suggest that 20 percent of the cells are heterozygous for the mutation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Caveats</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The expected 1:2 ratio of VAF:clone size may be affected by duplication or deletion of a copy of the gene. As an example, if the wild-type allele undergoes deletion, the VAF:clone size would be 1:1; conversely, if the wild-type allele undergoes gene duplication, the ratio would be &lt;1:2.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>VAF of 40 to 60 percent may be associated with a large hematopoietic clone, but it may also reflect germline heterozygosity (ie, inheritance of one mutant allele and one wild-type allele). Inherited mutations have been reported with <em>RUNX1, GATA2, DDX41, TP53, DNMT3A, TET2, </em>and other genes [<a href="#rid3">3-6</a>]; some of these germline mutations are associated with cancer predisposition syndromes or other conditions, as discussed separately. (See  <a class="medical medical_review" href="/d/html/93183.html" rel="external">"Familial disorders of acute leukemia and myelodysplastic syndromes"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>VAF near 100 percent may result from a germline polymorphism of an X-linked gene (eg,<em> BCOR, ZRSR2</em>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In some cases, CH-associated mutations may be due to somatic mosaicism [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/2898.html" rel="external">"Genetics: Glossary of terms", section on 'Mosaicism'</a>.)</p><p></p><p>With CH, one hematopoietic stem cell (HSC) gives rise to an outsized proportion of blood cells. Normal hematopoiesis in adults is a result of the collective contribution to blood cell production by 50,000 to 200,000 HSCs; if all stem cells were similarly active, an individual HSC would be expected to contribute to 0.002 to 0.0005 percent of blood cell production (ie, the reciprocal of the number of active HSCs) [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H1087118614"><span class="h1">MOLECULAR FEATURES</span></p><p class="headingAnchor" id="H2127122546"><span class="h2">CH-associated mutations</span><span class="headingEndMark"> — </span>The genes that are most frequently mutated in CH are also commonly mutated in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and myeloproliferative neoplasms (MPN). These genes are often referred to as "leukemia-associated genes" or "leukemia-driver genes" and they are thought to enable expansion of the clone due to a proliferative or survival advantage.</p><p>The frequency of specific mutations varies between studies, but the genes that are most often involved are <em>DNMT3A</em> and <em>TET2</em> [<a href="#rid1">1,8-11</a>].</p><p>Genes that are less often associated with CH include <em>ASXL1</em>, <em>JAK2, TP53,</em> <em>SF3B1, SRSF2, CBL</em>, <em>IDH1, IDH2, GNB1</em>, <em>BCOR</em>, <em>U2AF1</em>, <em>GNAS</em>, <em>PPM1D</em>, and <em>BCORL1</em> [<a href="#rid1">1,8-11</a>]. These genes reflect a broad array of cellular functions, including transcription factors, chromatin modifiers, DNA repair, ribonucleoprotein binding proteins, spliceosome components, signal transduction, and regulators of cellular metabolism, as described separately.<em> </em>(See  <a class="medical medical_review" href="/d/html/4483.html" rel="external">"Cytogenetics, molecular genetics, and pathophysiology of myelodysplastic syndromes/neoplasms (MDS)", section on 'Gene mutations'</a> and  <a class="medical medical_review" href="/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia", section on 'Molecular studies'</a>.)</p><p class="headingAnchor" id="H993908111"><span class="h2">Causes of CH</span><span class="headingEndMark"> — </span>CH is thought to result from accumulation of mutations throughout an individual's lifetime [<a href="#rid12">12</a>].</p><p>Most CH-associated mutations are thought to arise from endogenous mutagenic processes involving impaired DNA repair. As an example, a cytosine-to-thymine (C&gt;T) transition may result from spontaneous deamination of 5-methylcytosine to thymine [<a href="#rid9">9,13-16</a>]. Such nucleotide substitutions accumulate in the genome of hematopoietic stem cells at a rate of approximately 14 mutations per year; mutations in exons have been estimated to accumulate at a rate of approximately 1 every 10 years. Accumulation of mutations with clonal expansion in the absence of malignancy has also been reported in the esophagus, colon, brain, and other tissues [<a href="#rid17">17-19</a>].</p><p>Less commonly, CH-associated mutations may be related to environmental mutagens, such as ambient, occupational, diagnostic, or therapeutic radiation; tobacco smoke; air pollutants; and mutagenic drugs (eg, cancer chemotherapy) [<a href="#rid20">20-23</a>]. Rare cases of familial CH were reported in association with a syndrome of long telomeres and heterozygous mutations in <em>POT1</em> (protection of telomeres 1), which plays a role in telomere maintenance; however, potential contributions of mutated <em>POT1</em> or aberrant telomeres to familial CH or sporadic CH are presently uncertain [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H4252820314"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The prevalence of CH increases with age. Most cases occur sporadically, but family aggregates have been reported.</p><p>CH has been reported to account for ≥10 percent of circulating nucleated cells in ≥10 percent of adults in their mid-70s, 20 percent of 90-year-olds, and 30 percent of &gt;100-year-olds [<a href="#rid8">8-10,25,26</a>]. For perspective, the prevalence of unexplained clonal disorders in healthy 70-year-olds is &gt;100-fold higher than the prevalence of myelodysplastic syndromes (MDS) or leukemias [<a href="#rid1">1</a>].</p><p>Small clones (eg, variant allele fraction [VAF] ≥0.0001) are almost universally detectable in individuals &gt;40 years [<a href="#rid27">27</a>]. From a study in which an individual's blood cells served as a control for DNA sequencing of a solid tumor, one-quarter of patients had mutations in hematopoietic cells that were not found in the tumor; approximately 5 percent had mutations in leukemia-associated genes [<a href="#rid21">21</a>]. As described above, the prevalence of CH varies with the sensitivity of the detection technique, the genes that are interrogated, and the threshold for defining clonality, as described above. (See <a class="local">'Clonality'</a> above.)</p><p>In some cases, CH has been associated with Hispanic ethnicity, African ancestry, and germline variants of <em>MPL </em>(thrombopoietin receptor)<em>, </em>telomere-associated genes, and numerous genes of uncertain biological significance [<a href="#rid20">20,28-32</a>].</p><p class="headingAnchor" id="H4106670045"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>In addition to a history and physical examination, selected patients should undergo testing to exclude a hematologic malignancy, other causes of cytopenias (when present), and/or a germline mutation.</p><p>Clinical and laboratory evaluation for myelodysplastic syndromes, acute leukemias, and myeloproliferative neoplasms are described separately. (See  <a class="medical medical_review" href="/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"</a> and  <a class="medical medical_review" href="/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia"</a> and  <a class="medical medical_review" href="/d/html/4511.html" rel="external">"Overview of the myeloproliferative neoplasms"</a>.)</p><p class="headingAnchor" id="H446354704"><span class="h2">Clinical settings</span><span class="headingEndMark"> — </span>CH may be encountered in a variety of clinical settings and is usually detected by next-generation sequencing (NGS) of DNA, as described above. (See <a class="local">'Description and detection'</a> above.)</p><p>Settings in which CH may be encountered include:</p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation for cytopenia or another blood disorder</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone marrow examination for staging of multiple myeloma, lymphoma, or a non-hematopoietic neoplasm</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Testing for an inherited hematologic condition or genetic predisposition to cancer in a relative</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screening evaluation of a potential donor for hematopoietic cell transplantation (HCT)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic testing associated with a clinical trial</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Testing for plasma circulating cell-free DNA (cfDNA) or a paired blood sample for diagnostic solid tumor sequencing</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other testing, including direct-to-consumer (DTC) genetic testing</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation for premature cardiovascular events (see  <a class="medical medical_review" href="/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk", section on 'Older adults'</a>)</p><p></p><p class="headingAnchor" id="H487290450"><span class="h2">Further testing</span><span class="headingEndMark"> — </span>Further testing in a patient with CH is guided by the clinical setting, presence of hematologic findings, the nature of previous testing, and the size of the hematopoietic clone.</p><p class="headingAnchor" id="H4157624358"><span class="h3">Excluding a germline mutation</span><span class="headingEndMark"> — </span>We generally test dermal fibroblasts (or another non-hematopoietic somatic tissue) to exclude a germline mutation in cases when the variant allele frequency (VAF) is ≥25 percent or with a strong family history of cancer. As described above, VAF in that range may be due to genomic heterozygosity (ie, inheritance of one mutant allele and one wild-type allele) or somatic mosaicism. (See <a class="local">'Relation of VAF to clone size'</a> above.)</p><p class="headingAnchor" id="H2389842617"><span class="h3">Bone marrow examination</span><span class="headingEndMark"> — </span>We perform a bone marrow examination when cytopenias or other hematologic findings (eg, circulating blasts), would otherwise prompt the procedure (eg, to exclude a hematologic malignancy or aplastic anemia). In some situations, molecular findings alone (eg, <em>TP53 </em>mutation, ≥2 mutations in the hematopoietic clone) might prompt a shared decision between the clinician and the affected individual to perform a bone marrow examination because of a higher risk for a hematologic malignancy.</p><p>The role of a bone marrow examination and/or other evaluation of cytopenias is discussed separately. (See  <a class="medical medical_review" href="/d/html/13938.html" rel="external">"Approach to the adult with pancytopenia", section on 'Subsequent evaluation'</a>.)</p><p class="headingAnchor" id="H1126888647"><span class="h1">CLASSIFICATION OF CLONAL HEMATOPOIESIS</span><span class="headingEndMark"> — </span>Classification of CH is based on the variant allele frequency (VAF) and the presence of cytopenias and/or cellular dysplasia  (<a class="graphic graphic_table graphicRef122233" href="/d/graphic/122233.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H1083099868"><span class="h2">Clonal hematopoiesis of indeterminate potential (CHIP)</span><span class="headingEndMark"> — </span>CHIP has been defined as:</p><p class="bulletIndent1"><span class="glyph">●</span>VAF ≥2 percent (≥4 percent for X-linked gene mutations in males) of an acquired mutation of a leukemia-associated gene; the most common mutations affect <em>DNMT3A</em>, <em>TET2</em>, and/or <em>ASXL1, </em>but<em> </em>other recurrently mutated genes are also listed above. (See <a class="local">'CH-associated mutations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Normal peripheral blood counts. The diagnosis of CHIP specifically excludes patients with clinically significant cytopenias; such patients should instead be diagnosed with clonal cytopenia of uncertain significance (CCUS). (See <a class="local">'Clonal cytopenia of uncertain significance (CCUS)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No clinical or pathologic evidence for a World Health Organization (WHO)-defined hematologic malignancy [<a href="#rid1">1</a>].</p><p></p><p>A bone marrow examination is <strong>not</strong> required to diagnose CHIP, but it may be performed to exclude a hematologic malignancy, as described above. (See <a class="local">'Bone marrow examination'</a> above.)</p><p>Modest degrees of dysplasia and abnormalities of mean cell volume (MCV) or red cell distribution width (RDW) do not exclude the diagnosis of CHIP. However, if ≥10 percent of blood or bone marrow nucleated cells of one cell lineage exhibit dysplasia or if there is a disease-defining mutation, the condition should be classified as a myelodysplastic syndrome/neoplasm (MDS) or as acute myeloid leukemia (AML), according to the findings. (See  <a class="medical medical_review" href="/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia"</a>.)</p><p class="headingAnchor" id="H1701819256"><span class="h2">Clonal cytopenia of uncertain significance (CCUS)</span><span class="headingEndMark"> — </span>CCUS  (<a class="graphic graphic_table graphicRef122233" href="/d/graphic/122233.html" rel="external">table 1</a>) is defined by:</p><p class="bulletIndent1"><span class="glyph">●</span>VAF ≥2 percent of an acquired mutation of a leukemia-associated gene. (See <a class="local">'CH-associated mutations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unexplained cytopenia (ie, below the lower limit of normal for that laboratory) of at least one blood lineage, after an appropriate evaluation, as described separately. This is defined as Hb &lt;13 g/dL in males and &lt;12 g/dL in females for anemia, absolute neutrophil count &lt;1.8 ×10<sup>9</sup>/L for leukopenia, and platelets &lt;150 × 10<sup>9</sup>/L for thrombocytopenia. (See  <a class="medical medical_review" href="/d/html/13938.html" rel="external">"Approach to the adult with pancytopenia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No clinical or pathologic evidence for another defined hematologic malignancy neoplasm [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1">Exclusion of a hematologic malignancy for the purpose of diagnosing CCUS is described separately. (See  <a class="medical medical_review" href="/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"</a> and  <a class="medical medical_review" href="/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia"</a>.)</p><p></p><p>CCUS is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/121985.html" rel="external">"Idiopathic and clonal cytopenias of uncertain significance (ICUS and CCUS)"</a>.)</p><p class="headingAnchor" id="H687798730"><span class="h2">Aging-related clonal hematopoiesis (ARCH)</span><span class="headingEndMark"> — </span>ARCH is a loosely-defined term that refers to the presence of a detectable hematopoietic clone of any size (generally &lt;2 percent VAF), without other evidence of a WHO-defined hematopoietic malignancy  (<a class="graphic graphic_table graphicRef122233" href="/d/graphic/122233.html" rel="external">table 1</a>) [<a href="#rid1">1</a>].</p><p>When the VAF is ≥2 percent, the condition should be classified as either CHIP or CCUS  (<a class="graphic graphic_table graphicRef122233" href="/d/graphic/122233.html" rel="external">table 1</a>). (See <a class="local">'Clonal hematopoiesis of indeterminate potential (CHIP)'</a> above and <a class="local">'Clonal cytopenia of uncertain significance (CCUS)'</a> above.)</p><p class="headingAnchor" id="H2840491743"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of CH includes hematologic malignancies and other conditions that are associated with clonality. Indeed, clonality is a feature of a spectrum of disorders that range from the various types of CH to myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), acute myeloid leukemia (AML), and other hematologic malignancies.</p><p>In some cases, CH must be distinguished from an inherited (ie, germline) gene mutation, as discussed above. (See <a class="local">'Excluding a germline mutation'</a> above.)</p><p class="headingAnchor" id="H1822923453"><span class="h2">Hematologic malignancies</span><span class="headingEndMark"> — </span>Mutation of a leukemia-associated gene is a characteristic feature of hematologic malignancies. Compared with CH, hematologic malignancies (eg, MDS, AML, MPN) generally have a higher variant allele frequency (VAF), are more likely to have ≥2 mutations, and dysplasia and/or other morphologic abnormalities are usually more prominent  (<a class="graphic graphic_table graphicRef122233" href="/d/graphic/122233.html" rel="external">table 1</a>).</p><p>Bone marrow examination (including morphology, flow cytometry, cytogenetics, and molecular evaluation) may be needed to distinguish hematologic malignancies from CH. Clinical manifestations and diagnosis of MDS, AML, and MPNs are discussed separately. (See  <a class="medical medical_review" href="/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/4511.html" rel="external">"Overview of the myeloproliferative neoplasms", section on 'The classic myeloproliferative diseases'</a>.)</p><p class="headingAnchor" id="H1134530019"><span class="h2">Aplastic anemia/paroxysmal nocturnal hemoglobinuria</span><span class="headingEndMark"> — </span>Aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH) clinically overlap with one another and both disorders are associated with clonality and variable degrees of cytopenias. AA/PNH can be distinguished from CH by bone marrow biopsy (which will reveal substantial hypoplasia for AA), flow cytometry (which will reveal clones of CD59 negative cells in PNH), and genetic testing (eg, mutation of <em>PIGA</em> in most cases of PNH). Additional details of the clinical presentation and diagnosis of AA and PNH are provided separately. (See  <a class="medical medical_review" href="/d/html/7152.html" rel="external">"Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis", section on 'Evaluation'</a> and  <a class="medical medical_review" href="/d/html/7159.html" rel="external">"Clinical manifestations and diagnosis of paroxysmal nocturnal hemoglobinuria", section on 'Diagnosis and classification'</a>.)</p><p class="headingAnchor" id="H2598438701"><span class="h2">Inherited disorders</span><span class="headingEndMark"> — </span>Inherited disorders are usually detected in childhood, but some cases are first recognized in adulthood; adults with inherited syndromes may display only subtle hematologic or other abnormalities.</p><p>Importantly, a heterozygous germline mutation may be difficult to distinguish from an acquired mutation, especially when the VAF is close to 50 percent. As discussed above, an inherited disorder is distinguished by testing dermal fibroblasts or other somatic tissue for the mutation; an individual with a germline abnormality should have approximately the same VAF in blood/marrow as in other tissues. (See <a class="local">'Relation of VAF to clone size'</a> above.)</p><p>Presentation and diagnosis of familial hematologic syndromes are discussed separately. (See  <a class="medical medical_review" href="/d/html/93183.html" rel="external">"Familial disorders of acute leukemia and myelodysplastic syndromes"</a>.)</p><p class="headingAnchor" id="H3932689521"><span class="h1">OUTCOMES</span></p><p class="headingAnchor" id="H3203810440"><span class="h2">CHIP outcomes</span><span class="headingEndMark"> — </span>Clonal hematopoiesis of indeterminate potential (CHIP) is associated with decreased overall survival, increased risk for a hematologic malignancy, and a greater risk for cardiovascular complications, compared with age-matched members of the general population without CHIP [<a href="#rid9">9,10,28,33,34</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inferior survival</strong> – Compared with the general, age-matched population,<strong> </strong>CHIP is associated with increased all-cause mortality [<a href="#rid9">9,12,33</a>]. A retrospective review of 5132 individuals, with a median follow-up of 96 months, identified increased mortality in association with a CHIP-associated mutation (hazard ratio [HR] 1.4; 95% CI 1.1-1.8) [<a href="#rid9">9</a>]. Increased mortality was observed in those ≥70 years old, but not in younger individuals. Another series of 12,380 subjects found a similar risk of death in association with CHIP (HR 1.4, 95% CI 1.1-1.9) [<a href="#rid10">10</a>]. Most of the excessive mortality in individuals with CHIP was associated with coronary heart disease and ischemic stroke, rather than hematologic malignancies, as described below.</p><p></p><p class="bulletIndent1">Even without a mutation involving leukemia-driver gene, individuals with CH were reported to have higher rates of all-cause mortality compared to patients without CH [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased hematologic malignancies</strong> – Although only a small fraction of individuals with CHIP will develop a hematologic malignancy, CHIP is associated with an increased risk for transformation to myelodysplastic syndromes/neoplasms (MDS), myeloproliferative neoplasms (MPNs), or acute myeloid leukemia (AML). Rates of progression appear to vary with the specific mutations, the number of mutations, and the size of the hematopoietic clone [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1">The risk of evolution to AML has been estimated to be 0.5 to 1 percent per year [<a href="#rid35">35</a>]. As an example, CHIP was associated with an increased risk for developing a hematologic malignancy (HR 11.1, 95% CI 3.9-32.6) compared with individuals without CHIP based on whole exome sequencing of 17,182 people [<a href="#rid9">9</a>]. The prevalence of CHIP in 70-year-olds is at least 100-fold greater than the prevalence of MDS or AML, which indicates that the majority of individuals with CHIP do not go on to develop an overt hematologic malignancy [<a href="#rid1">1</a>]. For perspective, the risk of development of a hematologic malignancy in an individual with CHIP is an order of magnitude lower than the risk of progression from MDS to AML. Development of a hematologic malignancy following a diagnosis of CHIP is similar in magnitude to the rates at which monoclonal B cell lymphocytosis (MBL) or monoclonal gammopathy of undetermined significance (MGUS) evolve to non-Hodgkin lymphoma, myeloma, or another plasma cell or lymphoid neoplasm [<a href="#rid36">36,37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>More cardiovascular complications</strong> – CHIP is associated with an increased risk of cardiovascular diseases and worse outcomes in patients with heart failure. Examples of this association include:</p><p></p><p class="bulletIndent1">In a series that included &gt;17,000 people, CHIP was associated with an increased risk of coronary heart disease incidents (HR 2.0, 95% CI 1.2-3.4) and ischemic stroke (HR 2.6, 95% CI 1.4-4.8) [<a href="#rid9">9</a>]. In a separate analysis of nearly 8000 subjects from two prospective and two retrospective studies, carriers of CHIP had a risk of myocardial infarction that was two- to fourfold greater than non-carriers [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1">Survivors of myocardial infarction with CHIP have increased mortality and worsened heart failure outcomes [<a href="#rid35">35,38</a>].</p><p></p><p>The mechanism of increased cardiovascular events appears to be inflammation in the endothelium driven by clonally-derived monocytes/macrophages. Testing for CH in patients with premature or unexpected cardiovascular complications is discussed separately. (See  <a class="medical medical_review" href="/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a> and  <a class="medical medical_review" href="/d/html/1120.html" rel="external">"Overview of secondary prevention of ischemic stroke"</a>.)</p><p class="headingAnchor" id="H1473869407"><span class="h2">CCUS outcomes</span><span class="headingEndMark"> — </span>Clonal cytopenia of uncertain significance (CCUS) is associated with increased risk for progression to a hematologic malignancy, as described separately. (See  <a class="medical medical_review" href="/d/html/121985.html" rel="external">"Idiopathic and clonal cytopenias of uncertain significance (ICUS and CCUS)", section on 'Outcomes'</a>.)</p><p class="headingAnchor" id="H831877059"><span class="h2">ARCH outcomes</span><span class="headingEndMark"> — </span>Outcomes for individuals with aging-related clonal hematopoiesis (ARCH) are not well-defined.</p><p class="headingAnchor" id="H1033535843"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H1240291069"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Monitoring of<strong> </strong>the patient with CH should be individualized. We generally evaluate individuals every three to six months with an interval history, directed physical examination, and complete blood count (CBC) and differential. We suggest <strong>not</strong> routinely repeating DNA sequencing and <strong>not</strong> routinely repeating a bone marrow examination, unless there is another indication.</p><p>There is no optimal protocol or evidence-based guideline for monitoring an individual with CH. The nature and frequency of monitoring is influenced by the level of variant allele fraction (VAF), presence of cytopenias, and concerns of the clinician and affected individual. We may modify the frequency of visits and/or CBCs in individuals with certain clinical and genetic characteristics or an elevated <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.chrsapp.com%2F&amp;token=WMZE60FYz7u%2FJvW6bM8%2F%2FToQbY4UvYnoPji5eq3eAlk%3D&amp;TOPIC_ID=107866" target="_blank">CHRS score</a> (a prognostic model to estimate risk for development of a myeloid malignancy).</p><p>Features that we consider in establishing a monitoring protocol include:</p><p class="bulletIndent1"><span class="glyph">●</span>High-risk mutations (<em>SF3B1, SRSF2, ZRSR2, JAK2, TP53, RUNX1, FLT3, IDH1, or IDH2).</em></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VAF ≥20 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>≥2 distinct mutations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age ≥65 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Altered RBC indices (RDW ≥15 percent or MCV &gt;100 fL).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cytopenias, especially if associated with clinical findings (eg, cardiorespiratory compromise, infections, bleeding/bruising) and/or other associated cardiovascular risk factors.</p><p></p><p>Management of CH with associated cytopenias (eg, clonal cytopenia of uncertain significance [CCUS]) is discussed separately. (See  <a class="medical medical_review" href="/d/html/121985.html" rel="external">"Idiopathic and clonal cytopenias of uncertain significance (ICUS and CCUS)", section on 'Management'</a>.)</p><p class="headingAnchor" id="H87054001"><span class="h2">Counseling</span><span class="headingEndMark"> — </span>Counseling is an important aspect of management of CH. The emotional burden of potential cancer-associated mutations and the small risk of developing a hematologic malignancy in blood cells should be discussed. It is also important to emphasize that CH-associated mutations are acquired, and that the mutation does not affect relatives.</p><p>Modification of risk factors for cardiovascular complications is discussed separately. (See  <a class="medical medical_review" href="/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p><p class="headingAnchor" id="H719250424"><span class="h2">CH in potential transplant donors</span><span class="headingEndMark"> — </span>There is controversy about the suitability of an individual with CH as a donor for allogeneic hematopoietic cell transplant (HCT) [<a href="#rid39">39,40</a>]. Some institutions screen older potential donors for CH, as discussed separately. (See  <a class="medical medical_review" href="/d/html/3535.html" rel="external">"Donor selection for hematopoietic cell transplantation", section on 'Matched sibling donors'</a>.)</p><p>Recipient outcomes after receiving a transplant from a donor with CH involving <em>DNMT3A</em> or <em>TET2</em> are similar or superior to those from a donor without CH [<a href="#rid29">29,41</a>]. By contrast, the presence of CH involving MDS-associated genes, such as <em>TP53</em> or splicing factors, has been linked directly to development of donor cell leukemia [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H361176650"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Clonal hematopoiesis (CH) refers to a genetically distinct subpopulation of myeloid cells that share an acquired (ie, not inherited) mutation, which distinguishes them from other tissues and unaffected hematopoietic cells. CH may be detected in healthy individuals with few or no hematologic manifestations; although hematologic malignancies (eg, myelodysplastic syndromes/neoplasms, acute leukemias, myeloproliferative neoplasms) also exhibit clonality, they are generally associated with substantial hematologic findings.</p><p></p><p class="bulletIndent1">Categories of CH  (<a class="graphic graphic_table graphicRef122233" href="/d/graphic/122233.html" rel="external">table 1</a>) include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clonal hematopoiesis of indeterminate potential (CHIP)</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clonal cytopenia of undetermined significance (CCUS)</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Aging-related clonal hematopoiesis (ARCH)</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clonality</strong> – (See <a class="local">'Clonality'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Detection</strong> – CH is usually detected by next-generation sequencing (NGS) of DNA, but clonality is occasionally recognized by other molecular, cytogenetic, or immunophenotypic techniques. (See <a class="local">'Description and detection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Variant allele fraction (VAF)</strong> – The percentage of mutated DNA sequencing reads at a given genetic locus, which roughly parallels the size of the hematopoietic clone. (See <a class="local">'Relation of VAF to clone size'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CH-associated mutations</strong> – The genes that are most frequently mutated in CH are also commonly mutated in hematologic malignancies; they are often referred to as "leukemia-associated genes" or "leukemia-driver genes." (See <a class="local">'CH-associated mutations'</a> above.)</p><p></p><p class="bulletIndent1">The most frequently mutated leukemia-associated genes in CH are <em>DNMT3A </em>and <em>TET2. </em>Other genes are less-often associated with CH, but the frequency of specific mutations varies among studies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – The prevalence of CH increases with age. Most cases arise in a sporadic pattern, but there are reports of rare aggregates in families. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical settings</strong> – CH may be encountered in a variety of clinical settings in which testing reveals a subpopulation of myeloid cells that share an acquired (ie, non-germline) mutation. Examples of clinical settings are provided above. (See <a class="local">'Clinical settings'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Further testing</strong> – In selected cases, further testing should be performed to exclude an inherited condition (ie, germline mutation) or a hematologic malignancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – Classification of CH is based on the VAF and the presence of cytopenias and/or cellular dysplasia  (<a class="graphic graphic_table graphicRef122233" href="/d/graphic/122233.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Includes hematologic malignancies and other conditions associated with clonality, including myelodysplastic syndromes/neoplasms, myeloproliferative neoplasms, acute myeloid leukemia, and aplastic anemia/paroxysmal nocturnal hemoglobinuria. In some cases, CH must be distinguished from inherited disorders (ie, germline mutation). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – CHIP is associated with inferior overall survival, a modestly increased risk for developing a hematologic malignancy, and increased cardiovascular events. (See <a class="local">'CHIP outcomes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Monitoring of the individual with CH should be individualized. Counseling about risks and reassurance about outcomes are important aspects of management. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1">We generally evaluate individuals every three to six months with an interval history, directed physical examination, and complete blood count (CBC) and differential. We suggest <strong>not</strong> routinely repeating DNA sequencing and <strong>not</strong> routinely repeating a bone marrow examination, unless there is another indication.</p><p></p><p class="headingAnchor" id="H1605773920"><span class="h1">ACKNOWLEDGMENTS</span></p><p>The UpToDate editorial staff acknowledges the contributions of Stanley L Schrier, MD as Section Editor on this topic, his tenure as the founding Editor-in-Chief for UpToDate in Hematology, and his dedicated and longstanding involvement with the UpToDate program.</p><p>The UpToDate editorial staff acknowledges David P Steensma, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015; 126:9.</a></li><li><a class="nounderline abstract_t">Lucas F, Michaels PD, Wang D, Kim AS. Mutational analysis of hematologic neoplasms in 164 paired peripheral blood and bone marrow samples by next-generation sequencing. Blood Adv 2020; 4:4362.</a></li><li><a class="nounderline abstract_t">Batalini F, Peacock EG, Stobie L, et al. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis. Breast Cancer Res 2019; 21:107.</a></li><li><a class="nounderline abstract_t">Tatton-Brown K, Seal S, Ruark E, et al. Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability. Nat Genet 2014; 46:385.</a></li><li><a class="nounderline abstract_t">Tovy A, Reyes JM, Gundry MC, et al. Tissue-Biased Expansion of DNMT3A-Mutant Clones in a Mosaic Individual Is Associated with Conserved Epigenetic Erosion. Cell Stem Cell 2020; 27:326.</a></li><li><a class="nounderline abstract_t">Stremenova Spegarova J, Lawless D, Mohamad SMB, et al. Germline TET2 loss of function causes childhood immunodeficiency and lymphoma. Blood 2020; 136:1055.</a></li><li><a class="nounderline abstract_t">Lee-Six H, Øbro NF, Shepherd MS, et al. Population dynamics of normal human blood inferred from somatic mutations. Nature 2018; 561:473.</a></li><li><a class="nounderline abstract_t">Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014; 20:1472.</a></li><li><a class="nounderline abstract_t">Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371:2488.</a></li><li><a class="nounderline abstract_t">Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371:2477.</a></li><li><a class="nounderline abstract_t">Kwok B, Hall JM, Witte JS, et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood 2015; 126:2355.</a></li><li><a class="nounderline abstract_t">Watson CJ, Papula A, Poon YPG, et al. The evolutionary dynamics and fitness landscape of clonal haematopoiesis. bioRxiv [Epub, https://doi.org/10.1101/569566] 2019.</a></li><li><a class="nounderline abstract_t">Osorio FG, Rosendahl Huber A, Oka R, et al. Somatic Mutations Reveal Lineage Relationships and Age-Related Mutagenesis in Human Hematopoiesis. Cell Rep 2018; 25:2308.</a></li><li><a class="nounderline abstract_t">Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150:264.</a></li><li><a class="nounderline abstract_t">Alexandrov LB, Kim J, Haradhvala NJ, et al. The repertoire of mutational signatures in human cancer. Nature 2020; 578:94.</a></li><li><a class="nounderline abstract_t">Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature 2013; 500:415.</a></li><li><a class="nounderline abstract_t">Martincorena I, Fowler JC, Wabik A, et al. Somatic mutant clones colonize the human esophagus with age. Science 2018; 362:911.</a></li><li><a class="nounderline abstract_t">Keogh MJ, Wei W, Aryaman J, et al. High prevalence of focal and multi-focal somatic genetic variants in the human brain. Nat Commun 2018; 9:4257.</a></li><li><a class="nounderline abstract_t">Martincorena I, Roshan A, Gerstung M, et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 2015; 348:880.</a></li><li><a class="nounderline abstract_t">Loh PR, Genovese G, Handsaker RE, et al. Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. Nature 2018; 559:350.</a></li><li><a class="nounderline abstract_t">Coombs CC, Zehir A, Devlin SM, et al. Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell 2017; 21:374.</a></li><li><a class="nounderline abstract_t">Wong TN, Miller CA, Jotte MRM, et al. Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. Nat Commun 2018; 9:455.</a></li><li><a class="nounderline abstract_t">Aviv A, Levy D. Hemothelium, Clonal Hematopoiesis of Indeterminate Potential, and Atherosclerosis. Circulation 2019; 139:7.</a></li><li><a class="nounderline abstract_t">DeBoy EA, Tassia MG, Schratz KE, et al. Familial Clonal Hematopoiesis in a Long Telomere Syndrome. N Engl J Med 2023; 388:2422.</a></li><li><a class="nounderline abstract_t">Malcovati L, Cazzola M. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP). Hematology Am Soc Hematol Educ Program 2015; 2015:299.</a></li><li><a class="nounderline abstract_t">Link DC, Walter MJ. 'CHIP'ping away at clonal hematopoiesis. Leukemia 2016; 30:1633.</a></li><li><a class="nounderline abstract_t">Young AL, Tong RS, Birmann BM, Druley TE. Clonal hematopoiesis and risk of acute myeloid leukemia. Haematologica 2019; 104:2410.</a></li><li><a class="nounderline abstract_t">Zink F, Stacey SN, Norddahl GL, et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood 2017; 130:742.</a></li><li><a class="nounderline abstract_t">Frick M, Chan W, Arends CM, et al. Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol 2019; 37:375.</a></li><li><a class="nounderline abstract_t">Buscarlet M, Provost S, Zada YF, et al. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood 2017; 130:753.</a></li><li><a class="nounderline abstract_t">Bick AG, Weinstock JS, Nandakumar SK, et al. Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature 2020; 586:763.</a></li><li><a class="nounderline abstract_t">Kessler MD, Damask A, O'Keeffe S, et al. Common and rare variant associations with clonal haematopoiesis phenotypes. Nature 2022; 612:301.</a></li><li><a class="nounderline abstract_t">Jaiswal S, Natarajan P, Silver AJ, et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med 2017; 377:111.</a></li><li><a class="nounderline abstract_t">Bejar R. CHIP, ICUS, CCUS and other four-letter words. Leukemia 2017; 31:1869.</a></li><li><a class="nounderline abstract_t">Libby P, Sidlow R, Lin AE, et al. Clonal Hematopoiesis: Crossroads of Aging, Cardiovascular Disease, and Cancer: JACC Review Topic of the Week. J Am Coll Cardiol 2019; 74:567.</a></li><li><a class="nounderline abstract_t">Goldin LR, McMaster ML, Caporaso NE. Precursors to lymphoproliferative malignancies. Cancer Epidemiol Biomarkers Prev 2013; 22:533.</a></li><li><a class="nounderline abstract_t">Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354:1362.</a></li><li><a class="nounderline abstract_t">Dorsheimer L, Assmus B, Rasper T, et al. Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure. JAMA Cardiol 2019; 4:25.</a></li><li><a class="nounderline abstract_t">Gibson CJ, Lindsley RC. Stem cell donors should not be screened for clonal hematopoiesis. Blood Adv 2020; 4:789.</a></li><li><a class="nounderline abstract_t">DeZern AE, Gondek LP. Stem cell donors should be screened for CHIP. Blood Adv 2020; 4:784.</a></li><li><a class="nounderline abstract_t">Gibson CJ, Kim HT, Zhao L, et al. Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. J Clin Oncol 2022; 40:189.</a></li></ol></div><div id="topicVersionRevision">Topic 107866 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25931582" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32926123" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Mutational analysis of hematologic neoplasms in 164 paired peripheral blood and bone marrow samples by next-generation sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31533767" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24614070" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32673568" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Tissue-Biased Expansion of DNMT3A-Mutant Clones in a Mosaic Individual Is Associated with Conserved Epigenetic Erosion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32518946" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Germline TET2 loss of function causes childhood immunodeficiency and lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30185910" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Population dynamics of normal human blood inferred from somatic mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25326804" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Age-related mutations associated with clonal hematopoietic expansion and malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25426837" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Age-related clonal hematopoiesis associated with adverse outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25426838" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26429975" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The evolutionary dynamics and fitness landscape of clonal haematopoiesis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30485801" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Somatic Mutations Reveal Lineage Relationships and Age-Related Mutagenesis in Human Hematopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22817890" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The origin and evolution of mutations in acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32025018" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The repertoire of mutational signatures in human cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23945592" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Signatures of mutational processes in human cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30337457" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Somatic mutant clones colonize the human esophagus with age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30323172" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : High prevalence of focal and multi-focal somatic genetic variants in the human brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25999502" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29995854" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28803919" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29386642" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30592656" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hemothelium, Clonal Hematopoiesis of Indeterminate Potential, and Atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37140166" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Familial Clonal Hematopoiesis in a Long Telomere Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26637737" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27311932" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : 'CHIP'ping away at clonal hematopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31004019" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clonal hematopoiesis and risk of acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28483762" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30403573" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28655780" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33057201" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Inherited causes of clonal haematopoiesis in 97,691 whole genomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36450978" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Common and rare variant associations with clonal haematopoiesis phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28636844" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28592887" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : CHIP, ICUS, CCUS and other four-letter words.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31345432" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clonal Hematopoiesis: Crossroads of Aging, Cardiovascular Disease, and Cancer: JACC Review Topic of the Week.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23549397" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Precursors to lymphoproliferative malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16571879" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prevalence of monoclonal gammopathy of undetermined significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30566180" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32097457" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Stem cell donors should not be screened for clonal hematopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32097458" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Stem cell donors should be screened for CHIP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34793200" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
